Armistice Capital
Overview
Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund focused primarily on the health care and consumer sectors. The firm provides discretionary investment advisory services to private investment funds and employs a strategy that emphasizes capital preservation and risk mitigation through hedging.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Aligos Therapeutics | Oct 2023 | Private Placement | Co-investor |
| Tenaya Therapeutics | Feb 2024 | Follow-on Offering | Co-investor |
| Focus Universal Inc. | Apr 2026 | Private Placement | Co-investor |
For institutional investors. Book with your work email.
Key People
Harris Galitz
Portfolio Manager
Kevin Prendergast
Portfolio Manager
Michael Stern
Quantitative Portfolio Manager
Zachary Williams
Portfolio Manager - Healthcare
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Armistice Capital based?
Armistice Capital is headquartered in New York City, New York, United States.
When was Armistice Capital founded?
Armistice Capital was founded in 2012.
How many portfolio companies does Armistice Capital have?
Armistice Capital has 5 portfolio companies in Caplight's dataset.
What are some companies in Armistice Capital's portfolio?
Portfolio companies visible on Caplight include Aligos Therapeutics, Tenaya Therapeutics, Focus Universal Inc..
What was Armistice Capital's most recent investment shown here?
Armistice Capital's most recent investment in this portfolio sample was in Focus Universal Inc. in 2026.
What sectors does Armistice Capital focus on?
Armistice Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Telecommunications & Networking.
What company stages does Armistice Capital focus on?
Stage focus information for Armistice Capital is not publicly available.
What is Armistice Capital's AUM?
Armistice Capital's assets under management are estimated between $5.5B and $6.7B.